Management of progressive pulmonary fibrosis associated with connective tissue disease.
Interstitial lung disease
connective tissue disease
diagnosis
multidisciplinary consultation
progressive pulmonary fibrosis
treatment
Journal
Expert review of respiratory medicine
ISSN: 1747-6356
Titre abrégé: Expert Rev Respir Med
Pays: England
ID NLM: 101278196
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
2
8
2022
medline:
31
8
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
Fibrotic interstitial lung disease (ILD) is a frequent and severe complication of connective tissue disease (CTD). In this narrative review, we update the most relevant differential characteristics of fibrotic ILD associated with CTD (CTD-ILD) and propose a diagnostic and therapeutic approach based on a review of the articles published between 2002 and 2022 through PubMed. The subset of ILD, mainly the radiological/histological pattern and the degree of fibrotic component, usually determines the prognosis and therapeutic strategy for these patients. Some patients with CTD-ILD can develop progressive pulmonary fibrosis (PPF) with severe deterioration of lung function, rapid progression to chronic respiratory failure, and high mortality. PPF has been described in many CTDs, mainly in systemic sclerosis and rheumatoid arthritis, and requires a multidisciplinary diagnostic and therapeutic approach to improve patient outcomes.
Identifiants
pubmed: 35912842
doi: 10.1080/17476348.2022.2107508
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM